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Abstract
Background: Cocaine, particularly in its base form (’crack’), has become one of the drugs of most concern in the
Netherlands, being associated with a wide range of medical, psychiatric and social problems for the individual, and
with significant public order consequences for society. Available treatment options for cocaine dependent users are
limited, and a substantial part of the cocaine dependent population is not reached by the addiction treatment
system. Psychosocial interventions for cocaine dependence generally show modest results, and there are no
registered pharmacological treatments to date, despite the wide range of medications tested for this type of
dependence.
The present study (Cocaine Addiction Treatments to improve Control and reduce Harm; CATCH) investigates the
possibilities and problems associated with new pharmacological treatments for crack dependent patients.
Methods/Design: The CATCH-study consists of three separate randomised controlled, open-label, parallel-group
feasibility trials, conducted at three separate addiction treatment institutes in the Netherlands. Patients are either
new referrals or patients already in treatment. A total of 216 eligible outpatients are randomised using pre-
randomisation double-consent design and receive either 12 weeks treatment with oral topiramate (n = 36; Brijder
Addiction Treatment, The Hague), oral modafinil (n = 36; Arkin, Amsterdam), or oral dexamphetamine sustained-
release (n = 36; Bouman GGZ, Rotterdam) as an add-on to cognitive behavioural therapy (CBT), or receive a 12-
week CBT only (controls: n = 3 × 36).
Primary outcome in these feasibility trials is retention in the underlying psychosocial treatment (CBT). Secondary
outcomes are acceptance and compliance with the study medication, safety, changes in cocaine (and other drug)
use, physical and mental health, social functioning, and patient satisfaction.
Discussion: To date, the CATCH-study is the first study in the Netherlands that explores new treatment options
for crack-cocaine dependence focusing on both abstinence and harm minimisation. It is expected that the
study will contribute to the development of new treatments for one of the most problematic substance use
disorders.
Trial Registration: The Netherlands National Trial Register NTR2576
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Cocaine, particularly in its base form (’crack’), has
become one of the drugs of most concern in many
countries, being associated with a wide range of medical,
psychiatric and social problems for the individual, and
with significant public order consequences for society
[1-3]. In the Netherlands (16.7 million inhabitants),
annual cocaine-related addiction treatment demand
increased from 8,490 patients in 1994 to 17,270 in 2008,
and approximately half of this treatment demand in
2008 concerned users of crack [4]. Although the number
of treatment seeking cocaine users slightly decreased in
more recent years, the number of cocaine dependent
patients that repeatedly returned to addiction treatment
increased [5]. Despite its status as one of the most pro-
blematic addictions, reliable prevalence estimates of
cocaine dependence in the Netherlands are lacking. In
2005, 32,000 current cocaine users were identified in the
Netherlands [4], but this is likely to be a serious under-
estimation given the fact that the data were obtained in
a population survey. Moreover, the survey did not allow
a separate estimate of the prevalence of crack cocaine
use.
Psychosocial treatments for cocaine dependence,
which include cognitive behavioural therapy, counselling
and relapse prevention, have generally produced modest
results [6,7], and both study data and practice-based
experiences indicate that poor compliance is a major
complicating factor in these treatments. One of the
more promising psychosocial treatments for cocaine
dependence to date is contingency management, which
has shown positive results in terms of improved treat-
ment retention and reduction of substance use in a ser-
ies of studies [7-11], and is therefore currently being
investigated in the Netherlands in the context of a con-
trolled study in heroin addicts with concurrent cocaine
use. However, dissemination of contingency manage-
ment has been problematic because of low acceptance
and limited experience of therapists with this interven-
tion [12] and because contingency management is politi-
cally controversial because communities are often not
willing to just pay for a change in health behaviour [13].
The modest results of psychosocial treatments and the
increasing knowledge about the neurobiology of cocaine
dependence have led to an increasing number of studies
searching for effective pharmacological agents that influ-
ence the neurochemistry of cocaine, including antipsycho-
tics, anticonvulsants, antidepressants, psychostimulants
and (other) dopamine agonists [14-22]. Despite the con-
siderable efforts in this field, however, there are no proven
effective pharmacotherapies for cocaine dependence to
date, and the testing of new medications for cocaine
dependence should continue to be high on the research
agenda. Basically, the research efforts are focused on two
pharmacological strategies [23]: one directed at abstinence
from - or at least substantial reduction of - cocaine use
and the other directed at minimizing cocaine-related harm
by replacing short-acting, illicit cocaine by a long acting,
legal stimulant that can be taken orally [24-26].
Concerning the first strategy, from the wide range of
medications tested, topiramate and modafinil are exam-
ples of new medications that are currently only regis-
tered for indications other than cocaine dependence, but
have shown promise in several studies in cocaine depen-
dent populations in terms of abstinence or stimulant use
reduction [16,27,28].
Topiramate was originally marketed as an anticonvul-
s a n t .T h r o u g hi t se f f e c t so nt h eG A B A -a n dt h eg l u t a -
mate-system, it attenuates dopamine neurotransmission.
In the alcohol field, various randomised controlled trials
have shown that topiramate was more effective than pla-
cebo in treating alcohol dependence [29-31], and was at
least as effective as naltrexone [29,30]. Concerning
cocaine, topiramate was more effective in promoting
abstinence and sustained abstinence in (crack-) cocaine
users in a double-blind placebo-controlled pilot trial of
Kampman and colleagues [32], and cocaine craving sig-
nificantly decreased after the administration of topira-
mate in an open label trial [33]. A second promising
treatment option is the use of the alpha-adrenergic/glu-
tamate agonist modafinil, which is generally prescribed
for the treatment of narcolepsy, obstructive sleep
apnoea/hypopnoea and shift work sleep disorder. In
addition, modafinil showed effectiveness in terms of
duration of abstinence in the treatment of cocaine
dependence in two randomised controlled trials [34,35],
and in the reduction of craving in cocaine dependent
patients without comorbid alcohol dependence [36].
More recently, modafinil was investigated in metham-
phetamine dependence with improved treatment reten-
tion and decreased methamphetamine use as a result
[37-40].
With respect to the second strategy, harm reduction
or drug use reduction oriented treatment, a growing
number of pre-clinical and human studies suggest that
the monoamine releaser dexamphetamine, used for the
treatment of attention deficit hyperactivity disorder
(ADHD) and narcolepsy, is an important candidate for
replacement therapy [18,28]. The basic rationale for sub-
stitution treatment for cocaine dependence is similar to
that for other addictions (nicotine replacement therapy
in nicotine dependence, methadone and buprenorphine
in opioid dependence): it aims to replace uncontrolled
and harmful drug use with regulated and safer use, in
terms of dose, route of administration and adverse
effects, and to facilitate engagement with health care
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in treatment [41,42]. In addition, the regular supervised
prescription regimen may by itself help patients to
structure their daily life. In cocaine dependent patients
several controlled studies have shown significant
improvements associated with the administration of sus-
tained-release (SR) dexamphetamine, without serious
adverse events (including no serious cardiovascular
complications). Shearer and colleagues [43] reported
positive results of dexamphetamine SR in a placebo-con-
trolled study of cocaine dependent injectors in terms of
reduced cocaine use, craving, severity of dependence
and delinquent behaviour, and dexamphetamine SR was
f o u n dt oa t t e n u a t ec o c a i n eu s ea n di m p r o v et r e a t m e n t
retention in combined cocaine and heroin dependent
patients in controlled studies of Greenwald et al. [44]
and Grabowski et al. [45,46].
In sum, cocaine dependency is characterized by its
chronic and relapsing nature and by high treatment
dropout rates. A wide range of pharmacological agents
has been tested for efficacy in cocaine dependence, but
generally with disappointing or, at best, equivocal
results. From the investigated candidate medications,
topiramate, modafinil and dexamphetamine SR have
shown the most promising results. The vast majority of
these studies were conducted in the US, however, and
therefore these study findings need to be confirmed in
research outside the US.
The overall objective of the current study is to investi-
gate topiramate, modafinil, and dexamphetamine SR for
their acceptability and effectiveness in the treatment of
cocaine dependent patients in The Netherlands. Depen-
dent on the results, this study will also yield candidate
medications for further investigation in a large-scale
confirmatory trial. More specifically, we aim to evaluate
in three separate randomised controlled, open-label, par-
allel-group feasibility trials in crack-cocaine dependent
patients the response to each of these three medications,
as an add-on to psychosocial treatment with cognitive
behavioural therapy (CBT), compared to CBT alone, in
terms of acceptance, treatment retention and compli-
ance, efficacy, safety, and patient satisfaction. As in any
medication study, our primary focus is on the balance
between (potential) benefit and harm associated with
the medications, taking into consideration the personal
and societal damage linked to continued illicit use of
cocaine, in a situation without effective pharmacological
treatment options.
Because of the aim of the study - investigating treat-
ment effectiveness with both abstinence and harm mini-
misation as treatment strategies for cocaine dependent
patients - the study is named CATCH: Cocaine Addic-
tion Treatments to improve Control and reduce Harm.
Methods/Design
Research design
In each of the three sub-studies, patients are randomly
assigned to an experimental or control condition.
Patients in both conditions receive basic psychosocial
treatment in the form of outpatient cognitive-beha-
vioural therapy (CBT), and those in the experimental
group receive pharmacotherapy with one of the pro-
posed medications as an add-on to CBT.
In the largest series of studies of pharmacological
treatment options for cocaine dependence conducted to
date, the Cocaine Rapid Efficacy Screening Trials
(CREST), a randomised, controlled, parallel group, dou-
ble-blind design with an unmatched placebo was used
in all studies [47]. However, dropout rates in the control
groups were observed earlier during the active treatment
period, probably caused by inefficacy, and may have
biased outcomes (see [15,48]).
To avoid premature dropout by disappointment
about the absence of pharmacological effects in the
control groups, we decided not to use the conventional
double-blind placebo-controlled design. Instead, we
opted for a design in which patients in the control
conditions are unaware of the comparative experimen-
tal condition in which patients are prescribed active
medication. Central feature of this so-called pre-rando-
misation (or ‘Zelen’) design [49] is that randomisation
takes place prior to seeking (final) informed consent.
The variant we use is the so-called double-consent
design. Compared to the conventional randomised
design, the pre-randomisation double-consent design
offers the advantage of providing a more naturalistic
control condition, without information or selection
bias due to patients being aware that they are control
subjects, but with the strengths of a randomised
design. The double-consent design is considered parti-
cularly useful if the experimental intervention is
expected to be attractive to the participants, which is
likely to result in considerable disappointment, non-
compliance and loss to follow-up among control sub-
jects in a conventional randomised design.
All study participants are asked to provide informed
consent to participate in the psychosocial treatment
(CBT). After obtaining the (first) informed consent,
these patients are randomised to the experimental or
control condition, and only those in the experimental
c o n d i t i o na r ea s k e dt op r o v i d eas e c o n di n f o r m e dc o n -
sent to participate in the additional pharmacological
treatment. Hence, patients are only informed about the
assigned treatment, but not about the comparison treat-
ment. In Figure 1 the stepwise procedure according to
the pre-randomisation double-consent design is
displayed.
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Problematic crack-cocaine users  
First written informed consent to participate in CBT-study 
Baseline assessment 
Randomisation 
Control group: 
to receive CBT 
Experimental group: 
to receive CBT plus 1 of 3 medications 
Remaining inclusion criterion: be able and 
willing to participate in outpatient psychosocial 
treatment, supplemented with study medication 
and associated assessments 
Second written informed consent to 
participate in medication study 
Invitation to start study treatment 
Introduction & screening on eligibility: 
Inclusion criteria  Exclusion criteria 
a. at least 18 years old 
b. cocaine dependence previous year 

 
c. regular cocaine use in past month ( 8 days) 
d. cocaine administration primarily by 'basing' 
e. able and willing to participate in outpatient  
psychosocial treatment and associated assessments 
f. provide written informed consent  
g. earlier failed treatments (treatment refractory) 

 
a. severe medical and/ or psychiatric contra- 
 indication   
b. (wish for) pregnancy, lactation 
c. indication for treatment with naltrexone, 
    disulfiram, acamprosate, methylphenidate, 
    baclofen 
d. indication residential treatment 
e. insufficient command of Dutch language 
f. participation in another clinical scientific 
   (addiction) study 
Figure 1 Flowchart inclusion patients with respect to double-consent selection procedure. * Patients participating in the dexamphetamine
study must have a minimal duration of cocaine dependency of five years and a history of earlier failed treatments aimed at reducing or
abstaining from cocaine use.
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mittee of the Academic Medical Centre in Amsterdam,
the Netherlands (protocol number MEC 09/197).
Participants - setting
Since the use of crack-cocaine is most prevalent in the
urban western areas of the Netherlands, the three sub-
studies are executed at treatment sites in the three lar-
gest Western cities. In The Hague, topiramate is investi-
gated at Brijder Addiction Treatment; in Amsterdam,
modafinil is investigated at Arkin; and in Rotterdam,
dexamphetamine SR is investigated at Bouman GGZ.
In all three sub-studies, eligible patients must (a) be at
least 18 years old, (b) be cocaine dependent (DSM-IV)
during at least the previous year, (c) use cocaine on a
regular basis (i.e., ≥ 8 days) in the previous month, (d)
administer their illicit cocaine primarily by means of
basing (’crack’), (e) be able and willing to participate in
outpatient psychosocial treatment and associated assess-
ments (control condition), or be able and willing to par-
ticipate in outpatient psychosocial treatment
supplemented with the study medication and associated
assessments (experimental condition), and (f) have pro-
vided written informed consent with regard to their
assigned study treatment.
Patients are excluded in case of (a) severe medical (e.
g., severe renal insufficiency; cardiovascular problems)
or severe psychiatric problems (e.g. acute psychosis, cur-
rent major depression, suicidality) that constitute a con-
tra-indication for participation, (b) pregnancy or
continued lactation, (c) indication for treatment with
naltrexone, disulfiram, acamprosate, methylphenidate or
baclofen, (d) indication for residential treatment (clinical
judgment), (e) insufficient command of the Dutch lan-
guage, and (f) current participation in another addiction
treatment trial.
Given the nature of the medication and the social
debate on the use of dexamphetamine for the treatment
of cocaine dependence, in the sub-study with dexam-
phetamine SR, the required duration of cocaine depen-
dency is at least five years instead of one year.
Furthermore, these patients have to meet one additional
inclusion criterion: (g) a history of at least two failed
treatments directed at reduction of or total abstinence
from cocaine use (’treatment-refractory’).
Recruitment & Screening
Study participants are either new referrals to the addic-
tion treatment service with cocaine dependence as their
main problem or patients with cocaine dependence
already in treatment for another type of dependence, e.
g. methadone treatment for opioid dependence.
There are two eligibility screening sessions. In the first
session, the CATCH-study is explained and initial
eligibility criteria are examined. Study information and
informed consent forms are given to read before the
second screening session generally one week later. In
addition, baseline measurements are conducted.
In the second session, final eligibility is determined by
a physician, based on the health and medical status. Eli-
gible patients that agree to participate in the outpatient
psychosocial treatment (CBT) and study assessments are
asked to provide written informed consent. After this
(first) informed consent is obtained, patients are rando-
mised to one of the treatment conditions, i.e. with or
without pharmacotherapy. Patients in the experimental
group are then notified about the possibility to receive
pharmacological treatment as an add-on to CBT, and
are informed about the study medication and associated
study procedures. Only from these patients, a second
informed consent is obtained in a follow-up meeting
with the physician, usually one week later.
Psychosocial treatment
CBT in the experimental and control condition incorpo-
rates a combination of outpatient cognitive behavioural
counselling, relapse prevention and motivational inter-
viewing, which is considered a standard substance abuse
treatment in the Netherlands ("Leefstijltraining”) [50].
CBT is delivered in 12 weekly individual sessions of 45-
minutes by an experienced psychologist who received
formal training in CBT for the purpose of the trial.
Dependent on the treatment goal of the individual
patient, treatment is directed at stabilisation and harm
reduction, reduction of cocaine use, or total abstinence.
Pharmacological treatments
Each of the three proposed medications is prescribed for
a period of 12 weeks as an add-on to CBT in the experi-
mental group. Topiramate is titrated within three weeks
to a maximum oral dose of 200 mg/day, depending on
t h ep r o f i l eo fa d v e r s ee v e n t so b s e r v e d .D u r i n gt h ef i r s t
treatment week, topiramate is prescribed on a daily
basis at the treatment centre. In the remaining trial per-
iod, topiramate is dispensed to the patient once a week,
i.e. with take-home doses for a maximum of seven days.
Modafinil is prescribed in a fixed oral dose of 200 mg/
day during the first treatment week and in a maximum
dose of 400 mg/day during the remaining treatment
weeks. The prescription regimen of modafinil is similar
to that of topiramate (see above).
Dexamphetamine sulphate is prescribed in sustained-
release (SR) form, in a daily, oral fixed, dose of 60 mg.
To allow more intense safety monitoring and to prevent
diversion, dexamphetamine is prescribed on a daily basis
at the treatment centre during the first four weeks of
the trial period. In the remaining trial period, dexam-
phetamine is dispensed twice a week (take home doses
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first four weeks daily assessments of heart rate and
blood pressure are conducted, whereas in the remaining
treatment period assessments of heart rate and blood
pressure take place two times per week.
Assessments and instruments
Study assessments take place at baseline and at four,
eight (experimental group only) and 12 weeks (end-
point) following baseline. Table 1 gives an overview of
the instruments to be applied at baseline and follow-up
assessment points.
At baseline, the Composite International Diagnostic
Interview Substance Abuse Module (CIDI-SAM) [51] is
used to obtain DSM-IV [52] past year diagnoses of
cocaine use disorder and other substance use disorders,
the subsection ‘suicidal risk’ of the Mini-International
Neuropsychiatric Interview (MINI) to determine possi-
ble suicidality [53-55], and the Addiction Severity Index
(ASI) [56] to assess baseline demographics and clinical
characteristics.
At baseline and all subsequent time points, the Time
Line Follow-Back (TLFB) calendar method [57] is admi-
nistered to collect detailed information about the
patients’ self-reported cocaine use during the period
preceding each assessment. The short version of the
Obsessive Compulsive Drug Use Scale (OCDUS) is used
to measure cocaine craving [58-60], the Maudsley
Addiction Profile-Health Symptoms Scale (MAP-HSS)
[61] to assess physical status, and the Symptom Check-
list-90 (SCL-90) [62] to identify psychological problems.
All assessments following baseline are supplemented
with substance use items of the ASI and questions
about current illegal activities, income, and living
arrangements.
At the end of the study period (week 12), the Client
Satisfaction Questionnaire (CSQ-8) [63], supplemented
with questions about the received psychosocial and
pharmacological (experimental groups only) treatment is
added to assess patient satisfaction. Treatment adher-
ence is defined as the number of attended CBT sessions.
All these assessments are administered by specially
trained research assistants.
Medical assessments are conducted by a physician or
laboratory personnel and include: blood pressure, heart
rate, blood tests, ECG (dexamphetamine study only) and
a pregnancy test (women only) for all participants at
baseline. Participants of the experimental groups also
Table 1 Overview of assessments and instruments
Assessments (researchers) Baseline Week 4
￿ Week 8
￿ Week 12
Checklist inclusion criteria (control and experimental) ￿
CIDI - Substance Abuse Module (cocaine& heroine& alcohol) ￿
MINI - Suicidal risk ￿
Addiction Severity Index + supplement
1 ￿
Addiction Severity Index; short version substance use + supplement
1 ￿￿￿
Time Line Follow-Back (cocaine) ￿￿￿￿
Maudsley Addiction Profile (MAP) - HSS ￿￿￿￿
Symptom Check List- 90 (SCL-90) ￿￿￿￿
Obsessive Compulsive Drug Use Scale (OCDUS) ￿￿￿￿
Client Satisfaction Questionnaire- 8 (CSQ-8) + supplement
2 ￿
Evaluation (control and experimental) ￿
Medical assessment (physician) Baseline Week 4
￿ Week 8
￿ Week 12
Checklist exclusion criteria (control and experimental) ￿
First informed consent (control and experimental) ￿
Second informed consent (only experimental) ￿
Medical assessment: ECG (only dexamphetamine study) ￿￿
Medical assessment: blood analysis (week 12 only experimental) ￿￿
Medical screening: heart rate, blood pressure
3 (only experimental) ￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿
Pregnancy (only experimental; only women) ￿￿￿￿
(Serious) adverse events (only experimental) ￿ ￿￿￿￿ ￿￿￿￿ ￿￿￿￿
Drug accountability (only dexamphetamine study) ￿￿￿￿ ￿￿￿￿ ￿￿￿￿
Urinalysis cocaine- metabolites (control and experimental; obtained by research assistant) ￿￿ ￿ ￿ ￿
Treatment participation (consumption of care; medication) (control and experimental) ￿￿￿￿ ￿￿￿￿ ￿￿￿￿
Note.
￿ The assessments in week 4 and 8 are only for participants in the experimental groups (topiramate, modafinil, dexamphetamine SR),
1 The ASI-supplement
concerns illegal activities, income, and living arrangements,
2 Additional questions about the treatment(s),
3 In the dexamphetamine study, blood pressure and
heart rate will be assessed every day during the first four weeks, ￿￿￿￿Indicates weekly (instead of monthly) registration.
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study daily in the first four weeks), including blood pres-
sure and heart rate, and women are tested for pregnancy
monthly (see Table 1). At week 12, medical status of all
participants is evaluated, including blood tests and ECG
(dexamphetamine study only) for the experimental
groups.
Urine samples are collected by research assistants at
baseline, and at the four weeks preceding the endpoint
assessment, and are analysed on the presence of benzoy-
lecgonine (BE).
Remuneration
Patients receive a remuneration for their participation:
€30 for the baseline assessment, €15 for follow-up
assessments after four and eight weeks (experimental
groups only), and €30 for the endpoint assessment after
12 weeks. In addition, patients receive €15 for each
urine sample provided during the four weeks preceding
endpoint assessment. The maximum remuneration is
€150 in the experimental group and €120 in the control
group.
Outcome measures and data analyses
The study data are analysed following an intent-to-treat
(ITT) approach. The ITT-population consists of all
patients who provide informed consent pertaining to the
assigned treatment.
The primary outcome measure is treatment retention,
defined as the number of attended CBT sessions follow-
ing the start of treatment. In each sub-study, treatment
groups are compared on duration of treatment until
(premature or planned) termination, using a Cox pro-
portional hazards regression model. Compliance with
the study medication can on l yb ei n v e s t i g a t e di nt h e
experimental treatment conditions.
Secondary effects of the interventions are evaluated in
terms of treatment compliance, safety, cocaine use (self-
report; urinalyses), cocaine craving, use of other sub-
stances, physical and mental health, social functioning
(including criminality), and patient satisfaction. Pre- to
post-treatment changes in days of cocaine use from
baseline to week 12 are compared between the two
study groups in each sub-study using a 2 (time) × 2
(group) repeated measures ANOVA. Similar analyses
are conducted for changes in substance use other than
cocaine, and for other continuous and Likert-scaled out-
come measures.
Concerning the results of urinalyses, the outcome
measure is the sum of BE negative urine samples during
the four weeks preceding the endpoint assessment con-
sidering missing urine samples as positive. Negative BE
urines are compared between the two study groups and
evaluated for significant differences by means of an
analysis of variances model with the baseline urine sam-
ple as covariate.
Following the analyses pertaining to each of the three
sub-studies, the datasets from the sub-studies are pooled
to further explore the prognostic value of various patient
baseline characteristics with increased power.
Safety
Adverse events (AEs) are defined as any undesirable
medical experience occurring to a study subject during
the study. All AEs reported spontaneously by the sub-
ject or observed by the treating physician or his staff
are registered on a weekly basis by the treating physi-
cian, defining the relationship of each AE with the
study medication (definitely not, possibly, probably,
certainly, unknown), and its severity. If the AE is con-
sidered severe, it is registered as a serious adverse
event (SAE). All AEs will be followed until they have
abated, or until a stable situation has been reached. If
the AE is related to the study medication, it is defined
as an adverse reaction (AR) or - if severe - a serious
adverse reaction (SAR). An AR can be unexpected
when the nature or severity is not consistent with the
information in the study medications’ summary of pro-
duct characteristics. SAEs and SARs will be annually
reported to the medical ethical committee and the
medicine evaluation board.
SAEs that are both unexpected and at least possibly
related to the study medication are defined as suspected
unexpected serious adverse events (SUSARs). SUSARs
that arise during the study are reported within 15 days
after the first knowledge of the SUSAR, or within 7 days
in case of a fatal or life-threatening SUSAR to the medi-
cal ethical committee and the medicine evaluation board
of the Netherlands.
Power considerations
In the primary analysis, treatment effect is investigated
by means of a Cox proportional hazards regression
model. With a difference in 12-week survival between
the medication and control groups of 25% (i.e. 45% vs.
20%; hazard rate of 0.066 in the experimental condition
vs. 0.135 in the control condition), power of 0.80, and
two-sided alpha = 0.10, 36 patients are required in each
study group (2 × n = 36 in each medication sub-study;
total n = 3 × 2 × 36 = 216 patients). Given the feasibility
character of the study, as well as to enable testing of
various medications in one study, the sample sizes per
trial are necessarily limited. As in the earlier mentioned
CREST project, a lenient alpha of 0.10 was chosen to
minimize loss of statistical power due to small sample
sizes, instead of the usual 5% false-positive rate, which
would be more appropriate for future confirmatory
trials. Moreover, some earlier studies of modafinil and
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results with comparable sample sizes [34,43,45,46].
Discussion
Given the considerable number of problematic crack-
cocaine users and the lack of effective psychosocial and
pharmacological treatments, the CATCH-study is the
first study in the Netherlands that explores new phar-
macological treatment options for this type of addiction
that are not only focused on abstinence (CBT with or
without topiramate or modafinil), but also on harm
minimization using an agonist approach (CBT with or
without dexamphetamine SR). It is expected that the
study will contribute to opening up new lines of
research and - dependent upon the results - new lines
of treatment for one of the most problematic substance
use disorders: crack-cocaine dependence.
A limitation of this study is that control patients will
not receive placebo (in addition to their CBT) and that
experimenters’ bias towards the medication group can
not be eliminated due to the open-label design. How-
ever, given the high dropout rates in controls such as in
the CREST-studies, these disadvantages are defendable
in the context of the proposed feasibility trials.
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